Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Rhea-AI Summary
Anixa (NASDAQ: ANIX) announced that Dr. Jose Conejo-Garcia, co‑inventor of Anixa's FSHR‑mediated CAR‑T technology, will keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat on March 6, 2026. His keynote will discuss Anixa's ongoing Phase 1 trial of liraltagene autoleucel (lira‑cel), which uses the FSHR‑mediated CAR‑T approach first discovered by Dr. Conejo‑Garcia and team.
The SCTR 2026 Retreat will convene researchers, clinicians, and industry to showcase advances in cell therapy, immunotherapy, oncology, and cellular manufacturing.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ANIX slipped 1.37% while peers showed mixed moves: SRZN -1.7%, ADAG -1.41%, PYXS -6.58%, STTK +0.25%, TCRX flat. This pattern points to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | CAR-T survival update | Positive | +0.7% | Reported encouraging survival data and major dose escalation approval in ovarian CAR-T trial. |
| Feb 02 | Drug naming milestone | Positive | -3.3% | USAN approval of non-proprietary name liraltagene autoleucel for FSHR-targeted CAR-T therapy. |
| Jan 27 | Patent allowance | Positive | -0.3% | Notice of Allowance in Mexico for breast cancer vaccine patent expanding IP estate. |
| Dec 15 | IND transfer | Positive | -8.9% | Transfer of breast cancer vaccine IND from Cleveland Clinic and plans for Phase 2 trial. |
| Dec 11 | Positive Phase 1 data | Positive | -6.4% | Final Phase 1 breast cancer vaccine data met endpoints with 74% immune response rate. |
Recent history shows ANIX often trading down on otherwise positive clinical and IP updates, with only one of the last five news events aligning positively with price action.
Over the past few months, ANIX has reported multiple constructive updates, including encouraging ovarian CAR-T survival data, regulatory approval for major dose escalation, and global IP expansion for its breast cancer vaccine. Despite positive Phase 1 vaccine results and regulatory steps toward commercialization of lira-cel, four of the last five news events saw negative next-day price moves. Today’s keynote-related announcement fits into an ongoing narrative of clinical and translational progress centered on lira-cel and vaccine programs.
Regulatory & Risk Context
Anixa has an effective shelf registration on Form S-3 dated Sep 10, 2025, permitting issuance of various securities including common and preferred stock, warrants, and units. As of the latest data, usage_count is 0, so the shelf has not yet been tapped according to the provided context.
Market Pulse Summary
This announcement increases scientific visibility for Anixa’s FSHR-mediated CAR-T program, as its co-inventor keynotes a major 2026 translational research retreat and discusses the Phase 1 lira-cel trial. In context with recent data and regulatory steps around CAR-T and vaccines, it underscores the company’s emphasis on early-stage oncology innovation. Investors may watch for future clinical readouts, partnering developments, and financing decisions under the existing Form S-3 shelf registration.
Key Terms
car-t medical
phase 1 medical
cell-based therapies medical
AI-generated analysis. Not financial advice.
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology
Dr. Conejo-Garcia's keynote presentation will include a discussion of Anixa's ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, which utilizes the FSHR-mediated CAR-T therapy first discovered by Dr. Conejo-Garcia and his team at The Wistar Institute.
The SCTR 2026 Retreat will bring together pioneers in research, clinical care, and industry to showcase breakthrough innovations in advanced cell therapy, immune therapy, oncology, and cellular product manufacturing, and engage in empowering collaboration across the vibrant ecosystem, driving the future of medicine.
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-dr-jose-conejo-garcia-will-keynote-the-south-carolina-clinical--translational-research-institute-2026-retreat-302694019.html
SOURCE Anixa Biosciences, Inc.
FAQ
Who is Dr. Jose Conejo-Garcia and what is his role in Anixa's CAR-T technology (ANIX)?
When and where will Dr. Conejo-Garcia keynote the SCTR 2026 Retreat about ANIX technology?
What will Dr. Conejo-Garcia discuss about Anixa's Phase 1 lira‑cel trial (ANIX)?
What is liraltagene autoleucel (lira‑cel) and how does it relate to Anixa's pipeline (ANIX)?
What is the focus of the SCTR 2026 Retreat where ANIX technology will be presented?
